Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kona Medical

Request full access

Hypertension Therapy & Hypertension Treatment | Kona Medical

Bellevue, United StatesFounded 2009Biotech & Life Sciences

About Kona Medical

Kona Medical, Inc., established in 2009 by Michael Gertner, MD, is a medical technology company focused on developing a non-invasive treatment for resistant hypertension. The company's creation was rooted in combining Dr. Gertner's inventions with the assets of a preceding therapeutic ultrasound company, Therus Corporation. Dr. Gertner, a former general surgeon with a background in mechanical engineering, leveraged his experience to innovate in the medical device sector.

The company is developing the Surround Sound® Hypertension Therapy System, a device aimed at the multi-billion dollar renal denervation market. This market is experiencing significant growth, driven by the increasing prevalence of hypertension worldwide and a demand for minimally invasive treatment options. The Surround Sound system uses externally delivered, high-intensity focused ultrasound to ablate the renal nerves, which play a role in regulating blood pressure. A key differentiator of this technology is its non-invasive nature; it is designed to be performed outside of a catheterization lab, potentially reducing procedural complexity, cost, and risks associated with radiation or contrast media.

Kona Medical's business model centers on the development and eventual commercialization of this proprietary system, targeting patients with drug-resistant hypertension—a significant segment of the hypertensive population. The company has progressed its technology through several rounds of clinical trials outside the United States. Early and mid-stage trials (WAVE I, II, and III) demonstrated promising safety profiles and significant reductions in blood pressure. For instance, combined results from the WAVE I and II studies showed that 81% of patients had a clinically significant drop in systolic blood pressure at six months, with one study protocol reducing therapy time from 13 to just 3 minutes. A larger, sham-controlled trial, WAVE IV, was initiated to further validate these findings across multiple international sites. However, the technology remains investigational and is not yet approved by the U.S. Food and Drug Administration.

To finance its research and development, Kona Medical has successfully raised significant capital from a syndicate of medical technology investors. The company secured a total of $73.7 million over seven funding rounds, including a notable $30 million Series C round in May 2012 and a $10 million Series D in October 2013, which was specifically allocated for market development in China. Key investors include EW Healthcare Partners, Domain Associates, Morningside Group, and Morgenthaler Ventures. While the company showed considerable early promise and attracted substantial investment, it has been classified as a deadpooled company more recently, with its last funding round occurring in September 2015.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
43.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Sep 2015 $10M $40M Undisclosed —
SERIES DOther financing Oct 2013 $10M $40M Morningside —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Kona Medical website traffic

Latest recorded traffic for Kona Medical is 130 monthly website visits, up 18.2% over the last three months. Kona Medical's team grew 0% over the past year.

Latest monthly visits130 3-month web change+18.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Kona Medical in the Bellevue ecosystem

Live from Dealroom

The Kona Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

Other known investors1 additional known investor

  • University of Washington
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kona Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kona Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.